Home › Compare › JNDOF vs ABBV
JNDOF yields 3.09% · ABBV yields 3.06%● Live data
📍 JNDOF pulled ahead of the other in Year 3
Combined, JNDOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JNDOF + ABBV for your $10,000?
JINS HOLDINGS Inc., through its subsidiaries, engages in the planning, manufacturing, sales, and import/export of eyewear and fashion accessories in Japan. It offers airframes; computer glasses under the JINS SCREEN name; JINS Switch, an eyewear that uses magnet to attach sunglasses to frame; children's glasses; JINS VIOLET lenses for selectively block harmful light; JINS MEME, an eyewear, which enables visualization of one's physical and mental state; and contact lenses under the JINS 1DAY name through stores under the JINS Shibuya, JINS Harajuku, and rim of jins LUMINE Shinjuku names, as well through online and other channels. The company is also involved in the operation of shared workspaces; developing and selling work environment products; provision of workspace consulting; and contracting business for agriculture work. In addition, it operates bakery cafes. The company was formerly known as JINS Inc. and changed its name to JINS HOLDINGS Inc. in July 2019. JINS HOLDINGS Inc. was incorporated in 1988 and is headquartered in Tokyo, Japan.
Full JNDOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.